Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Qualigen

Qualigen

Qualigen is a Carlsbad, California-based biotechnology company developing therapeutic products for the treatment of cancer and infectious diseases founded in 1996 by Michael S. Poirier.

Qualigen is a biotechnology company that focuses on the developing and commercializing novel therapeutic products for the treatment of cancer and other infectious diseases, as well as the expansion of its flagship product, FastPack® diagnostic platform.

Its therapeutics pipeline includes cancer drug candidate compounds such as AS1411, ALAN, the RAS-F family of drug candidate compounds, as well as STARS, a DNA/RNA-based treatment device.

The company is committed to providing new therapeutic technologies to physicians and patients by combining its demonstrated ability to develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers like the University of Louisville.

Qualigen’s AS1411 cancer drug candidate uses synthetic DNA, known as an aptamer, to target and destroy tumor cells, without the serious side effects associated with other cancer therapies.

Timeline

May 19, 2021
Qualigen appoints Tariq Arshad, MD, MBA to the newly-created position of Senior Vice President, Chief Medical Officer.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Annalee Armstrong
August 17, 2021
FierceBiotech
The FDA wanted a couple more clinical studies for Qualigen's investigational COVID-19 antiviral before human testing, but the biotech is calling it quits instead. Infectious disease medicine QN-165 will be shelved for now, as Qualigen shifts focus instead to its oncology pipeline, including QN-247 and RAS-F for a variety of cancers.
BioSpace
November 5, 2020
BioSpace
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced today it has signed a contract with STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of WuXi AppTec, for GMP production of AS1411, Qualigen's lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials. Preclinical studies a
BioSpace
June 10, 2020
BioSpace
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today the signing of an exclusive license agreement with the University of Louisville (UofL) to facilitate development of Qualigen's AS1411 DNA aptamer as a drug candidate for the treatment of COVID-19, the disease caused by the novel coronav
BioSpace
May 19, 2020
BioSpace
Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) ("Ritter Pharmaceuticals", "Ritter" or the "Company"), announced today that, based upon the final vote count certified by the inspector of election for the special meeting of stockholders held on May 18, 2020, its stockholders approved all of the Qualigen, Inc. merger-related proposals, including: (i) the issuance of Ritter common stock and convertible preferred stock pursuant to the Agreement and Plan o

References

Golden logo
By using this site, you agree to our Terms & Conditions.